Proceedings of the American Thoracic Society Email Content Delivery
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Alton, E. W. F. W.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Alton, E. W. F. W.
The Proceedings of the American Thoracic Society 1:296-301 (2004)
© 2004 The American Thoracic Society

Use of Nonviral Vectors for Cystic Fibrosis Gene Therapy

Eric W. F. W. Alton on behalf of the United Kingdom Cystic Fibrosis Gene Therapy Consortium

Department of Gene Therapy, Imperial College London, National Heart and Lung Institute, London, United Kingdom

Correspondence and requests for reprints should be addressed to Prof. Eric W. F. W. Alton, M.D., Imperial College London, National Heart & Lung Institute, Department of Gene Therapy, Emmanuel Kaye Building, Manresa Road, London SW3 6LR, UK. E-mail: e.alton{at}imperial.ac.uk

Over the last decade, three groups within the United Kingdom (Edinburgh, Oxford, and Imperial College, London) have undertaken key studies in the development of clinical gene therapy for cystic fibrosis. In 2001, catalyzed by the Cystic Fibrosis Trust, these groups came together to form the United Kingdom Cystic Fibrosis Gene Therapy Consortium. The Consortium has removed duplication and competition, developed core facilities playing to the respective strengths of the centers, and introduced the joint strategy described in this article. This is driven by a clinical trial program, with a product pipeline and the necessary development of novel preclinical and human assays. The program is milestone-related, has a structure that lies between the pharmaceutical industry and academia, and has as its endpoint negotiations with industry to undertake a phase III clinical trial of the identified product.

Key Words: cystic fibrosis • gene therapy • lungs




This article has been cited by other articles:


Home page
 Proc Am Thorac SocHome page
S. M. Rowe, F. Accurso, and J. P. Clancy
Detection of Cystic Fibrosis Transmembrane Conductance Regulator Activity in Early-Phase Clinical Trials
Proceedings of the ATS, August 1, 2007; 4(4): 387 - 398.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 2004 by the American Thoracic Society.